These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23323324)

  • 1. [Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
    Nepoklonov AV; Kapitsa IG; Ivanova EA; Voronina TA; Val'dman EA
    Eksp Klin Farmakol; 2012; 75(11):3-6. PubMed ID: 23323324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative study of hemantane and amantadine effects on dopamine transporter expression in brain of normal and MPTP-treated C57BL/6 mice].
    Zimin IA; Logvinov IO; Antipova TA; Kovalev GI
    Eksp Klin Farmakol; 2011; 74(1):11-4. PubMed ID: 21476268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
    Kovalev GI; Salimov RM
    Eksp Klin Farmakol; 2011; 74(5):3-5. PubMed ID: 21809690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Estimation of the protective effect of the novel potential antiparkinsonian agent himantane against MPTP neurotoxicity].
    Val'dman EA; Nerobkova LN; Voronina TA
    Eksp Klin Farmakol; 2004; 67(1):7-10. PubMed ID: 15079899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].
    Katunina EA; Samoĭlova EV; Val'dman EA; Nerobkova LN; Voronina TA; Avakian GN
    Eksp Klin Farmakol; 2004; 67(2):16-8. PubMed ID: 15188753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
    Zimin IA; Kapitsa IG; Voronina TA; Kovalev GI
    Eksp Klin Farmakol; 2010 Nov; 73(11):2-5. PubMed ID: 21254589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
    Rojas P; Altagracia M; Kravsov J; Rios C
    Proc West Pharmacol Soc; 1992; 35():33-5. PubMed ID: 1502234
    [No Abstract]   [Full Text] [Related]  

  • 8. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of hemantane on bioelectric activity of brain in mice with MPTP-induced Parkinson syndrome].
    Kapitsa IG; Kokshenev II; Nerobkova LN; Val'dman EA; Voronina TA
    Eksp Klin Farmakol; 2013; 76(4):3-6. PubMed ID: 23762980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
    Reksidler AB; Lima MM; Dombrowski P; Andersen ML; Zanata SM; Andreatini R; Tufik S; Vital MA
    J Neurosci Methods; 2008 Jan; 167(2):268-77. PubMed ID: 17931705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)].
    Andiarzhanova EA; Val'dman EA; Kudrin VS; Raevskiĭ KS; Voronina TA
    Eksp Klin Farmakol; 2001; 64(6):13-6. PubMed ID: 11871228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
    Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
    Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
    Kapitsa IG; Ivanova EA; Kokshenev II; Nepoklonov AV; Val'dman EA; Voronina TA
    Eksp Klin Farmakol; 2014; 77(5):3-5. PubMed ID: 25033563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS].
    Logvinov IO; Antipova TA; Nepoklonov AV; Valdman EA
    Eksp Klin Farmakol; 2016; 79(1):12-4. PubMed ID: 27159951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The acute and subchronic effects of hemantane on [3H]-dopamine reuptake in rat striatal synaptosomes ex vivo].
    Abaimov DA; Kovalev GI
    Eksp Klin Farmakol; 2007; 70(4):11-4. PubMed ID: 18078034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.